Aleafia Health Inc. (TSX: AH, OTC: ALEAF) today announced that Janssen Pharmaceuticals, Inc., has approved its wholly owned subsidiary, Canabo Medical Inc. as an administrator and prescriber of antidepressant SPRAVATO® (esketamine) nasal spray. Three Canabo clinics, including the Company’s flagship Toronto location, along with a growing number of clinic network physicians and nurses, are now […]
The post Aleafia Health Approved by Janssen Pharmaceuticals to Administer Antidepressant SPRAVATO® appeared first on Technical420.
You may also like
-
Looking For Marijuana Stocks To Buy? 2 Analysts Expect To Have Upside In 2021
-
Trulieve Cannabis Corp. (TCNNF) Announces Closing of Public Offering and Full Exercise of Over-Allotment Option
-
Harborside Inc. (HBORF) Announces Upcoming Conference Participation
-
Cresco Labs Inc. (CRLBF) Expands Branded Edibles Portfolio With Launch of Wonder Wellness Gummies
-
Aphria Inc. (APHA) Announces Third Quarter Fiscal Year 2021 Results